Vismodegib CAS 879085-55-9

Disgrifiad o'r Cynnyrch:

Enw'r Cynnyrch: Vismodegib CAS 879085-55-9

 

Cyfystyron:

2-Chloro-N-[4-chloro-3-(2-pyridinyl)ffenyl]-4-(methylsulfonyl)benzamid;BROMO-1-NAPHTA

BenzaMide, 2-chloro-N-[4-chloro-3-(2-pyridinyl)ffenyl]-4-(Methylsulfonyl)-;

VisModegib (GDC-0449);

 

Priodweddau Cemegol a Ffisegol

Ymddangosiad: Gwyn i Solet Off-Gwyn

Assay: 99%+

Pwynt berwi: 561.6±50.0 gradd

Pwynt toddi:179-181 gradd

Pwysau Moleciwlaidd: 421.3

Dwysedd: 1.440

Pka:10.72±0.70

Sefydlogrwydd: Sefydlog am 2 flynedd o'r dyddiad prynu fel y'i cyflenwir. Gall hydoddiannau mewn DMSO neu ethanol gael eu storio ar -20 gradd am hyd at 3 mis.

 

Cais:

Vimodej targets SMO protein and inhibits Gli activation, thereby inhibiting downstream gene transcription and expression.For the treatment of locally progressive or metastatic basal cell carcinoma in adults who have recurred after surgery or are not well treated with surgery or radiotherapy; One of the most common skin cancers is basal cell carcinoma (BCC), which originates in the surface layer of the skin and does not cause pain to patients. The risk was greatest for skin diseases that were regularly exposed to the sun or ultraviolet light. The development and listing of Vimedji has brought good news to patients with BCC, and its clinical role is important and the target market is huge, and it has to grow into a "giant bomb" class (>$1 biliwn) cyffur yn y dyfodol.

 

 

 

Os oes gennych ddiddordeb yn ein cynnyrch neu os oes gennych unrhyw gwestiynau, mae croeso i chi gysylltu â ni!

 

 

Cynigir cynhyrchion o dan batent at ddiben Ymchwil a Datblygu yn unig. Fodd bynnag, mae'r cyfrifoldeb terfynol yn gorwedd gyda'r prynwr yn unig.

Tagiau poblogaidd: vismodegib cas 879085-55-9, gwneuthurwyr, cyflenwyr, ffatri, prynu, mewn stoc

• Pâr o: Tricine CAS % 7b{0}}
• Nesaf: Trametinib CAS 871700-17-3